Veterinary Diagnostics Institute™ (VDI) is a veterinary clinical ventures company dedicated to the research, development and introduction of innovative biomarkers for companion animals. Our initial product, NT-proBNP, a cardiac biomarker for canines and felines, was successfully introduced and sold to IDEXX which now promotes the product as CardioPet. Currently, VDI has fully validated a new biomarker for canine and feline lymphoma and canine hemagiosarcoma which we are actively promoting in the US. We also have a new biomarker for canine sepsis. VDI also runs the Glycominds laboratory - a CLIA certified lab performing proprietary biomarkers for Multiple Sclerosis.